These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25742136)

  • 1. Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.
    Kang J; Lee HJ; Kim J; Lee JJ; Maeng LS
    PLoS One; 2015; 10(3):e0118927. PubMed ID: 25742136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-Testis Antigen Expression in Serous Endometrial Cancer with Loss of X Chromosome Inactivation.
    Kang J; Lee HJ; Jun SY; Park ES; Maeng LS
    PLoS One; 2015; 10(9):e0137476. PubMed ID: 26360551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells.
    Sirchia SM; Ramoscelli L; Grati FR; Barbera F; Coradini D; Rossella F; Porta G; Lesma E; Ruggeri A; Radice P; Simoni G; Miozzo M
    Cancer Res; 2005 Mar; 65(6):2139-46. PubMed ID: 15781624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer.
    Winham SJ; Larson NB; Armasu SM; Fogarty ZC; Larson MC; McCauley BM; Wang C; Lawrenson K; Gayther S; Cunningham JM; Fridley BL; Goode EL
    Hum Mol Genet; 2019 Apr; 28(8):1331-1342. PubMed ID: 30576442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
    Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
    Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines.
    Benoît MH; Hudson TJ; Maire G; Squire JA; Arcand SL; Provencher D; Mes-Masson AM; Tonin PN
    Int J Oncol; 2007 Jan; 30(1):5-17. PubMed ID: 17143508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
    Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
    Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
    Buller RE; Sood AK; Lallas T; Buekers T; Skilling JS
    J Natl Cancer Inst; 1999 Feb; 91(4):339-46. PubMed ID: 10050867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer.
    Larson NB; Fogarty ZC; Larson MC; Kalli KR; Lawrenson K; Gayther S; Fridley BL; Goode EL; Winham SJ
    Genet Epidemiol; 2017 Dec; 41(8):898-914. PubMed ID: 29119601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients.
    Pedersen BS; Konstantinopoulos PA; Spillman MA; De S
    Genes Chromosomes Cancer; 2013 Sep; 52(9):794-801. PubMed ID: 23716468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
    Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
    Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
    Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
    Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
    Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
    Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
    Buekers TE; Lallas TA; Buller RE
    Gynecol Oncol; 2000 Mar; 76(3):418-22. PubMed ID: 10684722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing view of high-grade serous ovarian cancer.
    Berns EM; Bowtell DD
    Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.